Active	Status	Sponsor type	Region	Phase	Filter
11 Active 0 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ANGUILLE, Sébastien
WIDEA, NCT01686334 / 2012-001494-91: Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission	Active, not recruiting	2	130	Europe	DC vaccine	Zwi Berneman, Kom Op Tegen Kanker, Stichting tegen Kanker, Research Foundation Flanders	Acute Myeloid Leukemia	12/25	12/27
MESODEC, NCT02649829: Autologous Dendritic Cell Vaccination in Mesothelioma	Active, not recruiting	1/2	28	Europe	dendritic cell vaccination plus chemotherapy, chemoimmunotherapy	University Hospital, Antwerp, Kom Op Tegen Kanker, Stichting tegen Kanker	Malignant Pleural Mesothelioma	03/25	03/25
IMMUNICY-1, NCT04613557: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma	Active, not recruiting	1	18	Europe, US	CYAD-211, Endoxan, cyclophosphamide, Fludara, Fludarabine	Celyad Oncology SA	Relapse/Refractory Multiple Myeloma	12/22	02/37
ApoAML, NCT05506332: Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia	Recruiting	1	10	Europe	Venetoclax, 6-mercaptopurine	University Hospital, Antwerp	Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory	12/24	12/26
Meuleman, Nathalie
SCARLET, NCT04379817: Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients	Completed	2	23	Europe	Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT	Jules Bordet Institute	Multiple Myeloma	05/24	05/24
IMMUNICY-1, NCT04613557: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma	Active, not recruiting	1	18	Europe, US	CYAD-211, Endoxan, cyclophosphamide, Fludara, Fludarabine	Celyad Oncology SA	Relapse/Refractory Multiple Myeloma	12/22	02/37
NCT05289492: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma	Terminated	1	16	Europe, US	EOS884448, EOS-448, GSK4428859A, Belrestotug, Iberdomide, CC-220, Dexamethasone	iTeos Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline, iTeos Belgium SA	Multiple Myeloma	11/23	11/23
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)	Active, not recruiting	N/A	586	Europe, Japan, US, RoW	isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib	Sanofi	Plasma Cell Myeloma	02/26	02/26
NCT05426330: Advanced Cancer Patients' and Their Primary Caregivers' Willingness to Communicate About Advance Care Planning (ACP)	Recruiting	N/A	600	Europe		Jules Bordet Institute, Fonds Gaston Ithier, Université Libre de Bruxelles, Association Jules Bordet	Advanced Cancer	10/23	10/24
Breems, Local Investigator: Dimitri
WIDEA, NCT01686334 / 2012-001494-91: Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission	Active, not recruiting	2	130	Europe	DC vaccine	Zwi Berneman, Kom Op Tegen Kanker, Stichting tegen Kanker, Research Foundation Flanders	Acute Myeloid Leukemia	12/25	12/27
Site, SMPA Investigative
BBI-TP-3654-102, NCT04176198: A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis	Recruiting	1/2	240	Europe, Canada, Japan, US, RoW	Nusivertib, TP-3654, Ruxolitinib, Momelotinib	Sumitomo Pharma America, Inc.	Myelofibrosis	04/27	04/30